You are here

Newron Pharma

Eisai unit hands over $46M for Japanese rights to Newron’s schizophrenia add-on

Fierce Biotech

Sun, 12/15/24 - 10:48 pm

Newron's Schizophrenia Candidate Scores Mid-Stage Win, Moves to Phase III

BioSpace

Tue, 10/10/23 - 10:11 am

clinical trials

Newron’s Schizophrenia Candidate Gets Better Over Time

BioSpace

Fri, 02/17/23 - 09:38 am

Newron says pivotal treatment-resistant schizophrenia trial is a go

Pharmaphorum

Tue, 01/3/23 - 10:08 am

clinical trials

Newron's Merck KGaA-in licensed compound fails Rett Syndrome study, shares wilt

Endpoints

Mon, 05/4/20 - 10:32 am

clinical trials

Upcoming events – Obseva's first fibroid foray and Newron's test in Retts

EP Vantage

Fri, 09/6/19 - 10:12 am

clinical trials

uterine fibroids

Newron delays pivotal schizophrenia trials amid safety fears

Fierce Biotech

Tue, 05/28/19 - 10:34 am

clinical trials

After an odyssey of setbacks, FDA finally green-lights Newron’s Parkinson’s drug Xadago

Endpoints

Wed, 03/22/17 - 11:11 am

Parkinson's Disease

Newron faces further FDA delay for Parkinson's drug as regulator demands addiction evidence

Fierce Biotech

Wed, 03/30/16 - 11:00 am

Parkinson's Disease

Swiss Biotech IPOs May Revive Industry Starved of Investment

Bloomberg

Thu, 07/7/11 - 10:15 pm

Molecular Partners

Newron, Merck Serono conclude patient recruitment in Phase III MOTION study

Pharmaceutical Business Review

Wed, 06/29/11 - 07:30 am

Parkinson's Disease

Biotech's Latest Business Mishaps

Seeking Alpha

Mon, 05/10/10 - 09:19 am

Abbott Laboratories

Bristol-Myers Squibb

Dainippon Sumitomo